Loading...
VICTOR: vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: a retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland.
Hussain, S Ansari, J Huddart, R Power, D Lyons, Jeanette Wylie, James P Vilarino-Varlela, M Elander, N McMenemin, R Pickering, L
Hussain, S
Ansari, J
Huddart, R
Power, D
Lyons, Jeanette
Wylie, James P
Vilarino-Varlela, M
Elander, N
McMenemin, R
Pickering, L
Citations
Altmetric:
Abstract
There is no standard of care in the UK or Ireland for second-line chemotherapy for patients with advanced transitional cell carcinoma (TCCU). Vinflunine is approved for TCCU patients who have failed a platinum-based regimen, and is standard of care in Europe but is not routinely available in the UK. Data were collected retrospectively on patients who received vinfluine as a second-line treatment. The aims were to document the toxicity and efficacy in a real life setting. Data were collected on 49 patients from 9 sites across the UK and Ireland [median age, 64 (IQR, 57-70) years, 33 males]. All patients had advanced metastatic TCCU. Thirteen patients had bone or liver metastases, 4 patients had PS 2 and 11 patients had HB <10. Median vinflunine administration was 3.5 cycles (range 1-18). Most common grade 3-4 toxicities were constipation (4 patients) and fatigue (3 patients). Partial response rate was 29% (14 PR, 11 SD, 19 PD, 4 NE, 1 not available). Median OS was 9.1 (6.0, 12.7) months. Results are consistent with real life data from Europe. Toxicity is further reduced with prophylactic laxative and oral antibiotics. Vinflunine is an efficient and tolerable second line treatment in advanced TCCU.
Affiliation
Description
Date
2017-03
Publisher
Collections
Files
Keywords
Type
Article
Citation
VICTOR: vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: a retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. 2017, 50(3):768-772 Int J Oncol